Viridian Therapeutics, Inc.
VRDN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.19 | -0.43 | 0.16 | -0.39 |
| FCF Yield | -6.61% | -8.46% | -4.79% | -4.50% |
| EV / EBITDA | -10.44 | -11.62 | -18.49 | -17.63 |
| Quality | ||||
| ROIC | -19.82% | -14.95% | -12.59% | -11.42% |
| Gross Margin | 100.00% | 100.00% | -70.83% | 100.00% |
| Cash Conversion Ratio | 2.45 | 0.75 | 1.07 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 488.68% | -40.80% | -43.27% | -44.56% |
| Free Cash Flow Growth | 18.68% | -26.27% | -8.01% | -47.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 1.10 | 1.00 | 2.37 |
| Interest Coverage | -207.72 | -160.18 | -101.95 | -83.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 14.65 |